CXCL12 and pancreatic neoplasm: Alternatively, the neoadjuvant treatment preferentially kills tumor cells lacking CXCL12, resulting in the observed increase in chemokine ligand expression.Our data support that of Zhong et al., and indicate that CXCL12 expression is pathologically diminished in human pancreatic cancer compared to healthy human pancreatic exocrine ductal epithelium.